CIK 0001590750 · Large accelerated filer
Viridian Therapeutics, Inc.\DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471187261
- Phone
- 617.272.4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $348,194
- in 1 filing
Net −$348,194. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 15 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-03-10 | LEFKOFF KYLE Director | Sale | −3,300 | $14.31 | $47K | 463,473 |
| 2017-03-09 | LEFKOFF KYLE Director | Sale | −2,500 | $14.38 | $36K | 466,773 |
| 2017-03-08 | LEFKOFF KYLE Director | Sale | −5,000 | $14.70 | $74K | 469,273 |
| 2017-03-06 | LEFKOFF KYLE Director | Sale | −9,392 | $15.71 | $148K | 474,881 |
| 2017-03-06 | LEFKOFF KYLE Director | Sale | −608 | $16.24 | $10K | 474,273 |
| 2017-02-28 | LEFKOFF KYLE Director | Sale | −2,258 | $13.54 | $31K | 484,273 |
| 2017-02-27 | LEFKOFF KYLE Director | Sale | −1,500 | $13.79 | $21K | 486,531 |
| 2017-02-24 | LEFKOFF KYLE Director | Sale | −6,500 | $14.04 | $91K | 488,031 |
| 2017-02-23 | LEFKOFF KYLE Director | Sale | −1,800 | $13.65 | $25K | 494,531 |
| 2017-02-22 | LEFKOFF KYLE Director | Sale | −4,102 | $14.36 | $59K | 496,331 |
| 2017-02-16 | Leverone Jason A. CFO, Treasurer & Secretary | Grant or award · Stock Option (right to buy) | +77,500 | 77,500 | ||
| 2017-02-16 | RUBIN PAUL D EVP, Research & Development | Grant or award · Stock Option (right to buy) | +87,500 | 87,500 | ||
| 2017-02-16 | Levy Adam Scott Chief Business Officer | Grant or award · Stock Option (right to buy) | +87,500 | 87,500 | ||
| 2017-02-16 | Marshall William Stuart President & CEO | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2017-02-13 | LEBOW BENNETT S Director | Option exercise | +279,067 | $5.39 | $1.5M | 280,600 |
| 2017-02-13 | LEBOW BENNETT S Director | Grant or award · Unsecured Demand Promissory Note | +0 | |||
| 2017-02-13 | LEBOW BENNETT S Director | Option exercise · Unsecured Demand Promissory Note | −0 | 0 | ||
| 2017-02-08 | Gonyer David A Director | Option exercise | +1,200 | $7.65 | $9K | 1,899 |
| 2017-02-08 | Gonyer David A Director | Option exercise · Stock Option (Right to Buy) | −1,200 | 0 | ||
| 2017-02-03 | LEBOW BENNETT S Director | Option exercise | +1,200 | $7.65 | $9K | 1,533 |
Page 14 of 16 · 309 trades